title: Reduction in costs, blood products, and operating time in patients undergoing open heart surgery.
abstract: OBJECTIVE
  To test the hypothesis that use of aprotinin at hall dose would be more cost-effective or as efficacious as full-dose aprotinin or no aprotinin during open heart surgery.
  
  
  METHODS
  Cost-effective analysis, unmasked prospective comparison.
  
  
  METHODS
  Community hospital.
  
  
  METHODS
  One hundred thirty-three patients undergoing open heart surgery.
  
  
  METHODS
  Patients in 3 consecutive groups undergoing open heart surgery were allocated to receive no aprotinin, full-dose aprotinin, or half-dose aprotinin.
  
  
  METHODS
  Total cost (in dollars) of blood products administered plus cost of aprotinin at various dosages, comparison of total blood products administered during hospitalization, and closure time required in the operating room.
  
  
  RESULTS
  Full-dose and half-dose aprotinin significantly (P < .05) reduced the total blood products administered during hospitalization and the operating room closure time. However, use of half-dose aprotinin resulted in a significant cost savings (P < .05) when compared with either the cost of blood products required in the nodose aprotinin group or the cost of blood products plus aprotinin in the full-dose aprotinin group.
  
  
  CONCLUSIONS
  Use of aprotinin at half dose in a community hospital resulted in a significant reduction in costs, blood product use, and operating room closure time in patients undergoing open heart surgery.
authors.affiliation: Division of Cardiac Surgery, St Charles Medical Center, Bend, Ore, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Lazzara
authors.forename: F E
authors.initials: FE
authors.lastname: Kidwell
authors.forename: M F
authors.initials: MF
authors.lastname: Kraemer
authors.forename: J A
authors.initials: JA
authors.lastname: Wood
authors.forename: A
authors.initials: A
authors.lastname: Starr
mesh_terms: D000368:Aged; D007611:Aprotinin / Q000008:administration & dosage*; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D006348:Cardiac Surgical Procedures / Q000191:economics*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D006490:Hemostatics; D007611:Aprotinin